E Hermet1, A Cabrespine2, R Guièze2, A Garnier3, A Tempescul4, P Lenain5, R Bouabdallah6, J P Vilque7, J Frayfer8, D Bordessoule9, D Sibon10, M Janvier11, D Caillot12, P Biron13, L Legros14, B Choufi15, B Drenou16, N C Gorin17, K Bilger18, J Tamburini19, C Soussain20, S Brechignac21, J O Bay2. 1. Service de thérapie cellulaire et d'hématologie clinique adulte, Université d'Auvergne EA3846, CIC-501, CHU Clermont-Ferrand Hôpital Estaing, Clermont-Ferrand, France. Electronic address: ehermet@chu-clermontferrand.fr. 2. Service de thérapie cellulaire et d'hématologie clinique adulte, Université d'Auvergne EA3846, CIC-501, CHU Clermont-Ferrand Hôpital Estaing, Clermont-Ferrand, France. 3. Hôpital Pitié-Salpétrière, Paris, France. 4. Hôpital Augustin Morvan, Brest, France. 5. Centre Henri Becquerel, Rouen, France. 6. Institut Paoli Calmettes, Marseille, France. 7. Centre François Baclesse, Caen, France. 8. Centre Hospitalier de Meaux, Meaux, France. 9. Hôpital Universitaire Dupuytren, Limoges, France. 10. Hôpital Saint-Louis, Paris, France. 11. Centre René Huguelin, St Cloud, France. 12. Hôpital Le Bocage, Dijon, France. 13. Centre Leon Berard, Lyon, France. 14. Hôpital l'Archet, Nice, France. 15. Hôpital Duchenne, Boulogne/mer, France. 16. Hôpital Emile Muller, Mulhouse, France. 17. Hôpital St-Antoine, Paris, France. 18. Hôpital Hautepierre, Strasbourg, France. 19. Hôpital Cochin, Paris, France. 20. Institut Curie, Paris, France. 21. Hôpital Avicenne, Paris, France.
Abstract
INTRODUCTION: Limited data is available on the feasibility of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (AHSCT) in elderly patients over 70 years of age with non-Hodgkin's lymphoma (NHL). MATERIALS AND METHODS: In the setting of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) group, we retrospectively analyzed 81 consecutive patients with NHL over 70 years of age who received AHSCT. RESULTS: The median age at AHSCT was 72.3 years [70-80]. Patients' were diagnosed with diffuse large B-cell lymphoma (n=40), follicular lymphoma (n=16), mantle cell lymphoma (n=15), T-cell lymphoma (n=5), and other (n=5). Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) was 0 in 73% of patients. Main conditionings were BEAM (Carmustine-Etoposide-Cytarabine-Melphalan, n=61) and melphalan alone (n=14). Median delays to reach 0.5×10⁹/L neutrophils and 20 × 10(9)/L platelets were of 12 [9-76] days and 12 [0-143] days, respectively. One hundred day and one year cumulative incidence of NRM was 5.4% and 8.5%, respectively. The main cause of death remains relapse. CONCLUSION: In conclusion, this study revealed that AHSCT seemed to be acceptable in patients over 70 years of age with NHL. Patient age is not a limiting factor if clinical condition is adequate.
INTRODUCTION: Limited data is available on the feasibility of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (AHSCT) in elderly patients over 70 years of age with non-Hodgkin's lymphoma (NHL). MATERIALS AND METHODS: In the setting of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) group, we retrospectively analyzed 81 consecutive patients with NHL over 70 years of age who received AHSCT. RESULTS: The median age at AHSCT was 72.3 years [70-80]. Patients' were diagnosed with diffuse large B-cell lymphoma (n=40), follicular lymphoma (n=16), mantle cell lymphoma (n=15), T-cell lymphoma (n=5), and other (n=5). Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) was 0 in 73% of patients. Main conditionings were BEAM (Carmustine-Etoposide-Cytarabine-Melphalan, n=61) and melphalan alone (n=14). Median delays to reach 0.5×10⁹/L neutrophils and 20 × 10(9)/L platelets were of 12 [9-76] days and 12 [0-143] days, respectively. One hundred day and one year cumulative incidence of NRM was 5.4% and 8.5%, respectively. The main cause of death remains relapse. CONCLUSION: In conclusion, this study revealed that AHSCT seemed to be acceptable in patients over 70 years of age with NHL. Patient age is not a limiting factor if clinical condition is adequate.
Authors: Hewan Belete; Linda J Burns; Ryan Shanley; Manju Nayar; Brian McClune; Aleksandr Lazaryan; Veronika Bachanova; Nelli Bejanyan; Celalettin Ustun; Claudio Brunstein; Daniel J Weisdorf; Mukta Arora Journal: Am J Hematol Date: 2017-07-19 Impact factor: 10.047
Authors: Ingrid Glimelius; Karin E Smedby; Alexandra Albertsson-Lindblad; Michael J Crowther; Sandra Eloranta; Mats Jerkeman; Caroline E Weibull Journal: Blood Adv Date: 2021-03-23
Authors: Lova Sun; Shuli Li; Areej El-Jawahri; Philippe Armand; Bimalangshu R Dey; David C Fisher; Eric D Jacobsen; Caron A Jacobson; Ann S LaCasce; Steven L McAfee; Thomas R Spitzer; Yi-Bin Chen; Zachariah DeFilipp Journal: Oncologist Date: 2017-12-28
Authors: Pashna N Munshi; Yue Chen; Kwang W Ahn; Farrukh T Awan; Amanda Cashen; Geoffrey Shouse; Mazyar Shadman; Paul Shaughnessy; Joanna Zurko; Frederick L Locke; Aaron M Goodman; Jose C Villaboas Bisneto; Craig Sauter; Mohamad A Kharfan-Dabaja; Gabrielle Meyers; Samantha Jaglowski; Alex Herrera; Mehdi Hamadani Journal: Transplant Cell Ther Date: 2022-05-21